CRISPR Therapeutics AG (CRSP) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending September 2025, CRISPR Therapeutics AG (NASDAQ:CRSP) is held by 434 institutional firms.

• The collective stake of institutional investors in CRISPR Therapeutics AG moved to 81.0% in September 2025, a shift down from the 85.0% reported for June 2025.
• In percentage terms, this reflects as a holdings change of 1.72% quarter on quarter, and an increase of 5.60% year over year.
• During the quarter, 198 institutions bought more CRISPR Therapeutics AG shares, 141 sold shares, and 95 of the 434 total investors held their position steady.
• Collectively, institutional investors increased their stake in CRISPR Therapeutics AG to 73.66Mn shares as of September 2025, a change that is up by 1.25Mn shares quarter on quarter and up 13.70Mn shares year over year.
• As of September 30, 2025, ARK Investment Management LLC held CRISPR Therapeutics AG's largest shareholding position with over 9.79Mn shares, representing 10.76% of total outstanding shares.
• Among the most significant buyers of CRISPR Therapeutics AG during September 2025 were Orbis Allan Gray Ltd (2.22Mn), SR ONE CAPITAL MANAGEMENT, LP (989.81K), BlackRock, Inc. (983.79K), MORGAN STANLEY (886.48K), STATE STREET CORP (736.64K).
• Leading sellers of CRISPR Therapeutics AG stock in September 2025 included TWO SIGMA ADVISERS, LP (771.73K), NATIONAL BANK OF CANADA /FI/ (725.78K), NEA Management Company, LLC (529.28K), UBS Group AG (504.52K), TWO SIGMA INVESTMENTS, LP (501.28K).
• The top 10 institutional holders of CRISPR Therapeutics AG for the quarter ending September 2025 included ARK Investment Management LLC (9.79Mn), BlackRock, Inc. (7.05Mn), Capital International Investors (5.65Mn), Orbis Allan Gray Ltd (4.98Mn), STATE STREET CORP (4.01Mn), T. Rowe Price Investment Management, Inc. (3.28Mn), VANGUARD GROUP INC (2.36Mn), UBS Group AG (2.34Mn), Amova Asset Management Americas, Inc. (2.16Mn), Sumitomo Mitsui Trust Group, Inc. (2.16Mn).